Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles tagged with "ACR Convergence 2020"

State of the Art Session Reviews Lupus Causes, Potential Treatments

Vanessa Caceres  |  November 20, 2020

ACR CONVERGENCE 2020—Rheumatologists and patients have struggled with a lack of new therapies for systemic lupus erythematosus (SLE), but a better understanding of the underlying mechanisms behind the disease helps shed light on potential treatments. That was the theme of the ACR Convergence session State of the Art: Lupus—The Future Is Now, led by Peggy…

Top Research in Lupus Presented at ACR Convergence 2020

David S. Pisetsky, MD, PhD  |  November 20, 2020

ACR CONVERGENCE 2020—Held Nov. 5–9, the ACR’s first fully virtual annual meeting is a wrap, but that doesn’t mean it’s too late to catch the highlights. Dozens of research abstracts on various aspects of lupus were presented during the fully virtual event, and David S. Pisetsky, MD, PhD, professor of medicine and immunology at Duke…

Dr. Ethan Craig Picks His Favorite Gout Abstracts from ACR Convergence 2020

Keri Losavio  |  November 19, 2020

In light of the release of the ACR’s new gout guideline, it’s not surprising that 50 abstracts of studies on various aspects of gout were accepted at ACR Convergence 2020. Here, we highlight just a few:

Anti-TNF Treatment Trial Encouraging for High-Risk APS Pregnancies

Thomas R. Collins  |  November 19, 2020

Early results in a phase 2 trial are finding that adding a TNF blocker to other treatment could greatly lower the risk of serious complications during pregnancy for women who have antiphospholipid syndrome with lupus anticoagulant.

ACR Convergence graphic

Racial Disparities Persist in OA & RA Management

Thomas R. Collins  |  November 19, 2020

From pain management to arthroplasty, African American patients with OA and RA experience worse outcomes than white patients. But the reasons for these health disparities are difficult to parse from socioeconomic and cultural factors.

Optimize Gout Management with the Latest Evidence-Based Guidance

Mary Beth Nierengarten  |  November 17, 2020

ACR Convergence 2020—In May 2020, the ACR published its updated guideline for the management of gout.1 It followed on the heels of a 2017 gout guideline published by the American College of Physicians.2 Although the guidelines provide similar recommendations on the treatment of acute gout, they differ importantly in the use of uric acid-lowering therapy…

Synopsis: Single Cell Technologies & New Insights into SLE

Lara C. Pullen, PhD  |  November 16, 2020

ACR CONVERGENCE 2020—The definition of cell type depends increasingly on a cell’s molecular features. On Friday, Nov. 6, 2020, Alex Kuo, PhD, senior scientist at Stanford University School of Medicine, Stanford, Calif., described six technologies that are relatively mature and can be used for rheumatic disease research: Rapidly developing single-cell RNA sequencing (scRNA-seq); Cellular indexing…

Investigation Continues on Repurposed Rheumatology Therapies for COVID-19 Cytokine Storm

Ruth Jessen Hickman, MD  |  November 14, 2020

Roberto Caricchio, MD, discusses what trials of repurposed rheumatology drugs to treat COVID-19 cytokine storm have shown so far.

Food for Thought: On Eating & Inflammation in Rheumatic Disease

Susan Bernstein  |  November 14, 2020

Certain nutrients or dietary patterns may affect inflammation and rheumatic disease risk in certain populations. Recommended nutrients include omega-3 fatty acids found in fish, poultry or nuts. Following a Mediterranean or standard Western diet may affect RA risk too.

A Close Look at Antibodies in RA

Carina Stanton  |  November 13, 2020

ACR CONVERGENCE 2020—Recent research findings suggest rheumatologists need to take a closer look at two gold standard autoantibodies used to diagnose seropositive rheumatoid arthritis (RA)—rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP), according to Caroline Grönwall, PhD, and Miriam Shelef, MD, PhD, who discussed Antibodies in RA: Beyond Citrullination & Back to Rheumatoid Factor at…

  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 10
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences